Dr Reddy's expands European operations with launch of generics in France

First products, to be available in the hospital market, will belong to oncology & anti-infectives

Dr Reddy's completes acquisition of product portfolio from Teva

premium

BS B2B Bureau Hyderabad

Last Updated : Feb 14 2017 | 4:13 PM IST

Dr Reddy’s Laboratories Ltd will expand its commercial operations in Europe with the introduction of its portfolio of generics in France. The first products will be made available in the hospital market in March 2017 in the area of oncology and anti-infectives, including antimycotics.

The company recently launched select products of its hospital portfolio in Italy and Spain, and is looking to further strengthen its presence in the two countries with the launch of anti-HIV products this year.

Abhijit Mukherjee, chief operating officer, Dr Reddy’s Laboratories, said, “It is our constant endeavor to enhance the reach of our affordable and difficult-to-produce drugs. Our business expansion in Europe is a testimony to Dr Reddy’s commitment to ensure access to affordable medicine for patients across the globe.”

With a diversified portfolio of injectables and complex generics, Dr Reddy’s currently has two R&D centres, one manufacturing and a packaging & storage facility in Europe.